Fresenius in patent dispute over hypocalcemia treatment
07-12-2021
Sanofi victorious at Fed Circ in prostate cancer drug dispute
15-08-2019
Amgen wins biosimilars case against Apotex at Federal Circuit
06-07-2016
jhvephoto / Shutterstock.com
Fresenius Kabi has submitted a petition for inter partes review (IPR) of US patent number 9,856,287, a patent owned by Amgen.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Amgen, Fresenius Kabi, inter partes review, IPR, PTAB, refolding proteins, Neupogen, Neulasta, biosimilars
